TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26470910

Group type: EXPERIMENTAL
Intervention: Residents performing ≥50% of distal anastomoses in on-pump CABG
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Residents performing ≥50% of distal anastomoses in off-pump CABG
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Attending surgeons performing distal anastomoses in on-pump CABG
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Attending surgeons performing distal anastomoses in off-pump CABG
Number of subjects: 1272
Study: 24382638

Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) 750 mg q8h plus peginterferon (180 μg/week) and ribavirin (1,000-1,200 mg/day)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Peginterferon/ribavirin (PR48) alone
Number of subjects: 578
Study: 21500996

Group type: EXPERIMENTAL
Intervention: Estroprogestagen therapy (EP)
Number of subjects: 78
Study: 19719534

Group type: EXPERIMENTAL
Intervention: Active heat recovery ventilators (HRV)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo heat recovery ventilators (HRV)
Number of subjects: 68
Study: 17848814

Group type: EXPERIMENTAL
Intervention: Structured physical training program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard complex rehabilitation program
Number of subjects: 63
Study: 15612844

Group type: EXPERIMENTAL
Intervention: Telephone-based monitoring and brief counseling intervention (TEL)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Standard 12-step group counseling (STND)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 359
Study: 11734711

Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal vaccine VA‐MENGOC‐BC (2 doses)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal vaccine VA‐MENGOC‐BC (3 doses)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal vaccine VA‐MENGOC‐BC
Number of subjects: 105
Study: 9403267

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) ethanol solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine (CH) ethanol
Number of subjects: 0
Study: 7959609

Group type: EXPERIMENTAL
Intervention: Resistance training program (12 weight-lifting exercises, 3 sets of 8 repetitions, 3 times per week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 14
Study: 3300707

Group type: EXPERIMENTAL
Intervention: Gold-plated tympanostomy tubes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Teflon tympanostomy tubes
Number of subjects: 28
Study: 31588833

Group type: EXPERIMENTAL
Intervention: Standard-length CWMT (45 min/session, 25 sessions, n = 29)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Shortened-length CWMT (15 min/session, 25 sessions, n = 32)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waitlist group (n = 28)
Number of subjects: 89
Study: 29868911

Group type: EXPERIMENTAL
Intervention: High-nitrate (HN) vegetables (∼200 g/d; ∼150 mg nitrate/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-nitrate (LN) vegetables (∼200 g/d; ∼22 mg nitrate/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no increase in vegetables; ∼6 mg nitrate/d)
Number of subjects: 30
Study: 26940938

Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily
Number of subjects: 493
Study: 24565357

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: SRT
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: COMB
Number of subjects: 488

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 488
Study: 23553866

Group type: EXPERIMENTAL
Intervention: 2.5 mg fluoride
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5 mg fluoride
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 10 mg fluoride
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 19682880

Group type: EXPERIMENTAL
Intervention: Escin (60mg daily, 30mg every 12 hours for 2 months)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Escin
Number of subjects: 219
Study: 17559717

Group type: EXPERIMENTAL
Intervention: Inducing rumination
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Inducing distraction
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Rumination and stress interaction
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Negative attentional bias
Number of subjects: 81
Study: 15826880

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (5 mg daily, n = 36)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 74
Study: 12812355

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg in a single oral dose
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg/day for three days)
Number of subjects: 98
Study: 15536661

Group type: EXPERIMENTAL
Intervention: Saint GERVAIS water application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bidistilled water
Number of subjects: 0
Study: 10451079

Group type: EXPERIMENTAL
Intervention: Computer assisted educational intervention about appropriate utilization of Arthrotec (diclofenac + misoprostol)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Generic information about OA (control condition)
Number of subjects: 252
Study: 7786658

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12
Study: 2241595

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 190

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 190
Study: 738065

Group type: EXPERIMENTAL
Intervention: Left visual field (LVF) presentation of faces
Number of subjects: 80

Group type: COMPARATOR
Intervention: Right visual field (RVF) presentation of faces
Number of subjects: 80

Group type: COMPARATOR
Intervention: Left visual field (LVF) presentation of letter pairs
Number of subjects: 80

Group type: COMPARATOR
Intervention: Right visual field (RVF) presentation of letter pairs
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7-year-old group with LVF presentation of faces
Number of subjects: 80

Group type: COMPARATOR
Intervention: 7-year-old group with RVF presentation of letter pairs
Number of subjects: 80
Study: 28917242

Group type: EXPERIMENTAL
Intervention: Comprehensive school-based intervention
Number of subjects: 9867

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9867
Study: 25977929

Group type: EXPERIMENTAL
Intervention: High maternal BMI
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Pregnancy weight-gain exceeding 40 pounds
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: High blood sugar
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Diagnosed and treated gestational diabetes
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Single abnormal glucose tolerance test (no diagnosis of gestational diabetes)
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: BMI and pregnancy weight-gain
Number of subjects: 2305
Study: 22889696

Group type: EXPERIMENTAL
Intervention: HIV/AIDS educational intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 90
Study: 21699364

Group type: EXPERIMENTAL
Intervention: Hydrogel dressing
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vaseline® cream (placebo)
Number of subjects: 15
Study: 19188505

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 300
Study: 16904540

Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 624
Study: 15005829

Group type: EXPERIMENTAL
Intervention: Green tea (caffeine 104 mg/d, catechins 573 mg/d, 323 mg epigallocatechin gallate)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Green tea (with high caffeine consumption)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Green tea (with low caffeine consumption)
Number of subjects: 104
Study: 11737400

Group type: EXPERIMENTAL
Intervention: HAART plus interleukin-2 (IL-2) and hydroxyurea
Number of subjects: 22

Group type: COMPARATOR
Intervention: HAART only
Number of subjects: 22
Study: 9094924

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment through height and weight measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food intake assessment through two 24-h recalls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of nutrient intakes
Number of subjects: 0
Study: 8216453

Group type: EXPERIMENTAL
Intervention: Gel formulation (Iprogel)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hydrophilic ointment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Emulsion cream (reference product)
Number of subjects: 6
Study: 29940521

Group type: EXPERIMENTAL
Intervention: Extended Clinical Management (E-CM)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Psychoeducational Cognitive Behavioural Group Therapy (PCBT-G)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: PCBT-G plus 16 outpatient individual treatment sessions (PCBT-G+I)
Number of subjects: 177

Group type: COMPARATOR
Intervention: PCBT-G and PCBT-G+I
Number of subjects: 177

Group type: COMPARATOR
Intervention: PCBT-G+I
Number of subjects: 177

Group type: COMPARATOR
Intervention: PCBT-G
Number of subjects: 177
Study: 27136509

Group type: EXPERIMENTAL
Intervention: Cold water immersion (8.9±0.6°C; 9 min with 1 min out of water, repeated twice)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (players remained seated for 20 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 24452826

Group type: EXPERIMENTAL
Intervention: Removable dental prostheses (RDP)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Shortened dental arches (SDA)
Number of subjects: 152
Study: 22634125

Group type: EXPERIMENTAL
Intervention: Surgical resection (RES)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 168
Study: 20456065

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 400

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Desflurane (deep anesthesia removal)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Desflurane (awake removal)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Isoflurane (deep anesthesia removal)
Number of subjects: 400
Study: 18221346

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) Teacher Classroom Management and Child Social and Emotion curriculum (Dinosaur School)
Number of subjects: 1768

Group type: COMPARATOR
Intervention: Control group (matched pairs of schools)
Number of subjects: 1768
Study: 15752125

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (0.005%) applied twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Narrow-band UVB phototherapy
Number of subjects: 20
Study: 12750166

Group type: EXPERIMENTAL
Intervention: rhAPC (24 microg/kg per hour)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11105478

Group type: EXPERIMENTAL
Intervention: Just deserts motive for punishment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Likelihood of committing future offenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain tumor identified as cause of violent action
Number of subjects: 0
Study: 8873178

Group type: EXPERIMENTAL
Intervention: Specific plus variable group (practised at the target distance and at distances around the target)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Specific group (practised only at the specified target distance)
Number of subjects: 26
Study: 1514500

Group type: EXPERIMENTAL
Intervention: 5 mg nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (matched to nifedipine doses)
Number of subjects: 30
Study: 6469553

Group type: EXPERIMENTAL
Intervention: Clorurated aminoacid solution (10% solution, 1 liter daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acetated aminoacid solution (10% solution, 1 liter daily)
Number of subjects: 10
Study: 31448837

Group type: EXPERIMENTAL
Intervention: SRP (scaling and root planning)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP + AM (375 mg amoxicillin and 250 mg metronidazole, 8/8 hours, 7 days)
Number of subjects: 24
Study: 28826825

Group type: EXPERIMENTAL
Intervention: Doxycycline-streptomycin-hydroxychloroquine (DSH)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Doxycycline-streptomycin (DS)
Number of subjects: 177
Study: 27505191

Group type: EXPERIMENTAL
Intervention: Educational video about generic medicines
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Generic ibuprofen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 70
Study: 24618349

Group type: EXPERIMENTAL
Intervention: Tailored intervention (n=10)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tailored intervention (n=7)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study: 22591195

Group type: EXPERIMENTAL
Intervention: CK‐2017357 at 250 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CK‐2017357 at 500 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 20177164

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 18070263

Group type: EXPERIMENTAL
Intervention: Clinical pathways (CP)
Number of subjects: 115
Study: 15290118

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4) 10 mg kg(‐1) body weight over 30 min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (hypercholesterolaemic subjects)
Number of subjects: 19
Study: 12013167

Group type: EXPERIMENTAL
Intervention: Sharp expansion
Number of subjects: 945

Group type: COMPARATOR
Intervention: Blunt expansion
Number of subjects: 945
Study: 10202392

Group type: EXPERIMENTAL
Intervention: 3 g mixed tea oral administration and topical treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo and glycerin treatment
Number of subjects: 59
Study: 8748361

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented enteral nutrition (0.35 g of glutamine/kg body weight per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isonitrogenous formula (0.05 g of glutamine/kg body weight per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented enteral nutrition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isonitrogenous formula
Number of subjects: 30
Study: 2220176

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NEA) therapy, 50 mg/day for 6 months followed by a 6-month pause, continued for up to 5 years post-op.
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no NEA therapy) after surgery.
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no NEA therapy) after irradiation.
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NEA) therapy.
Number of subjects: 196
Study: 730416

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride (50 + 5 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 30626425

Group type: EXPERIMENTAL
Intervention: Blood plasma levels of Ang-2, FGF-2, HGF, VEGF, PDGF-β, IL-8, TNF-α, TIMP-1, and TIMP-2 determined at diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGF-2, HGF, VEGF, and PDGF-β plasma levels at diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratification based on levels of CAFs at diagnosis and their variations after therapy
Number of subjects: 0
Study: 29980224

Group type: EXPERIMENTAL
Intervention: Decrease in daily GH dose (IGF‐1 target level of -2 to -1 SDS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Increase in daily GH dose (IGF‐1 target level of 1 to 2 SDS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Decrease in IGF‐1 levels in females within the low treatment arm
Number of subjects: 32
Study: 27713968

Group type: EXPERIMENTAL
Intervention: Whole natural almonds (42 g per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Whole roasted almonds (42 g per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chopped almonds (42 g per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almond butter (42 g per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (0 g per day)
Number of subjects: 18
Study: 24585791

Group type: EXPERIMENTAL
Intervention: Modified Ravitch repair (Group A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic repair using metal stabilizers (Group B)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic repair using absorbable stabilizers (Group C)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Open surgical repair (Group A)
Number of subjects: 31
Study: 22322237

Group type: EXPERIMENTAL
Intervention: Terlipressin (group A, N=23)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Noradrenaline (group B, N=23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Terlipressin (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Noradrenaline (group B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 46
Study: 19919888

Group type: EXPERIMENTAL
Intervention: Pentax-AWS®
Number of subjects: 32

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 32
Study: 17397559

Group type: EXPERIMENTAL
Intervention: HMR Calorie System training
Number of subjects: 44
Study: 16619162

Group type: EXPERIMENTAL
Intervention: Virtual phenotype interpretation arm
Number of subjects: 318

Group type: COMPARATOR
Intervention: Rule-based interpretation arm
Number of subjects: 318
Study: 12144196

Group type: EXPERIMENTAL
Intervention: Prospective observational studies of confirmed bites with correct identification of the creature.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration between biologists/taxonomists and clinical management services.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine follow-up of patients after bites.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of databases from prospective studies.
Number of subjects: 0
Study: 10517189

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg/day and doxycycline 200 mg/day for 45 days (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days (group 2)
Number of subjects: 40
Study: 8748595

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 27
Study: 2044726

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 24
Study: 6284840

Group type: COMPARATOR
Intervention: Enhanced monocyte and neutrophil ADCC in patients with severe psoriasis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal basal cAMP levels and cAMP responses during ADCC reaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal degranulation as determined by lysozyme release during ADCC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased hexose monophosphate shunt activation in effector cells during cytotoxic reaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal activity of enzymes responsible for respiratory burst
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal oxygen consumption and degranulation following phagocytosis of opsonized zymosan particles in neutrophils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased binding of IgG-sensitized erythrocytes by monocytes
Number of subjects: 0
Study: 30944968

Group type: EXPERIMENTAL
Intervention: Oral dissolution therapy (ODT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy (SWL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined SWL and ODT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined treatment (ODT + SWL)
Number of subjects: 150
Study: 30536479

Group type: EXPERIMENTAL
Intervention: cis100+RT (high-dose cisplatin 100 mg/m2 on days 1, 22, and 43)
Number of subjects: 62

Group type: COMPARATOR
Intervention: cis40+ART (intermediate-dose cisplatin weekly 40 mg/m2)
Number of subjects: 62
Study: 28191913

Group type: EXPERIMENTAL
Intervention: LY2409021 20 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 25824211

Group type: EXPERIMENTAL
Intervention: Oritavancin 1,200 mg single dose
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 297
Study: 23516964

Group type: EXPERIMENTAL
Intervention: Noise masker
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Babble masker
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both conditions (noise and babble)
Number of subjects: 55
Study: 21851906

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg
Number of subjects: 40
Study: 19724269

Group type: EXPERIMENTAL
Intervention: Intensive GMA (two sessions per week)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Routine weekly GMA (one session per week)
Number of subjects: 163